Guardant Health News: Latest Advancements in Cancer Detection
Cancer can be a daunting diagnosis for anyone. However, thanks to advancements in technology and medicine, the future for cancer detection and treatment is looking bright. One company that is at the forefront of this innovation is Guardant Health.
Guardant Health is a precision oncology company that develops liquid biopsy technologies for cancer detection. Recently, the company has made significant advancements in cancer detection that have the potential to revolutionize how we approach cancer screening.
What is Liquid Biopsy Technology?
Liquid biopsy technology is a non-invasive method of detecting cancer by analyzing a patient’s blood plasma for cancer cells or cancer DNA. This technology is particularly useful for detecting cancers that are difficult to diagnose with traditional methods, such as pancreatic or ovarian cancer.
Guardant Health’s liquid biopsy technology, Guardant360, is a comprehensive genomic profiling test that detects alterations in a patient’s DNA that are associated with cancer. The test is highly sensitive and can detect alterations in DNA that are present in as little as one part in 10,000.
Advancements in Cancer Detection
Guardant Health’s liquid biopsy technology has made significant advancements in cancer detection. In June 2021, the company announced that it had received FDA approval for its Guardant360 CDx test, which is the first liquid biopsy test approved for comprehensive genomic profiling of solid tumors.
The test is designed to identify targetable genomic alterations in the DNA of patients with advanced cancer. This information can help doctors tailor treatment plans that are specific to each patient’s genomic profile, resulting in better outcomes and potentially longer survival rates.
Guardant Health has also developed the GuardantOMNI test, which is a liquid biopsy test that can detect alterations in DNA that are associated with all cancer types. The test is highly accurate, with a sensitivity of up to 94%.
Benefits of Liquid Biopsy Technology
The benefits of liquid biopsy technology are manifold. For one, it is a non-invasive method of detecting cancer that is less painful and less expensive than traditional screening methods. Additionally, it is a highly sensitive method of detecting cancer, which means it can detect cancer at an earlier stage, resulting in better treatment outcomes.
Another benefit of liquid biopsy technology is that it can be used to monitor a patient’s response to treatment. By analyzing a patient’s blood plasma for alterations in DNA associated with cancer, doctors can monitor the effectiveness of treatment and make adjustments as needed.
Conclusion
In conclusion, Guardant Health’s liquid biopsy technology has made significant advancements in cancer detection. Its Guardant360 and GuardantOMNI tests have the potential to revolutionize how we approach cancer screening and treatment.
The benefits of liquid biopsy technology are numerous, and with FDA approval for comprehensive genomic profiling of solid tumors, it has become an important tool in the fight against cancer. As technology advances, we can only expect these benefits to continue to grow, giving hope to the millions of people around the world affected by cancer.
